← Leaderboards
Jin Q Cheng
University Of South Florida
$7,546,777
Attributed
$7,546,777
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $779.4K · FY2005–16$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$7,546,777 · 6
By mechanism
R01$7,334,370 · 5
R29$212,407 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of South Florida
Same institution · by research overlap
- Said M Sebti$16,720,811
Others in their field
Top investigators on “Oncogenes”
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- David Heimbrook · Leidos Biomedical Research, Inc.$73,747,183
- Scott W Lowe · Sloan-Kettering Inst Can Research$36,382,798
- John Blenis · Harvard University (Medical School)$29,103,255
- Andrea Califano · Columbia University Health Sciences$28,006,523
- Robert Neil Eisenman · Fred Hutchinson Cancer Research Center$27,166,845
Research focus
OncogenesApoptosisBaseEctopic ExpressionMalignant NeoplasmsCell SurvivalNeoplasm /Cancer GeneticsTherapeutic TargetMalignant - DescriptorCancer CellResistanceGenesRegulationCell ProliferationPlayTumorigenesisCancer TherapyStagingLaboratory MouseDiagnosisCharacteristicsChemotherapyLoss Of FunctionPromotor (Genetics)
Grant awards (27)
IKBKE/IKKE (epsilon) Kinase in Non-small Cell Lung Cancer$349,638
R01 · FY2016 · CA · contact PI
IKBKE/IKKE (epsilon) Kinase in Non-small Cell Lung Cancer$349,638
R01 · FY2015 · CA · contact PI
IKBKE/IKKE (epsilon) Kinase in Non-small Cell Lung Cancer$339,148
R01 · FY2014 · CA · contact PI
IKBKE/IKKE (epsilon) Kinase in Non-small Cell Lung Cancer$328,659
R01 · FY2013 · CA · contact PI
MicroRNAs in Human Ovarian Cancer$315,962
R01 · FY2013 · CA · contact PI
IKBKE/IKKE (epsilon) Kinase in Non-small Cell Lung Cancer$349,638
R01 · FY2012 · CA · contact PI
MicroRNAs in Human Ovarian Cancer$336,129
R01 · FY2012 · CA · contact PI
MicroRNAs in Human Ovarian Cancer$336,129
R01 · FY2011 · CA · contact PI
MicroRNAs in Human Ovarian Cancer$346,525
R01 · FY2010 · CA · contact PI
MicroRNAs in Human Ovarian Cancer$346,352
R01 · FY2009 · CA · contact PI
Disruption of AKT Pathway for Cancer Intervention$382,942
R01 · FY2008 · CA · contact PI
Disruption of AKT Pathway for Cancer Intervention$321,809
R01 · FY2007 · CA · contact PI
AKT2 Oncogene and Human Oncogenesis$228,571
R01 · FY2007 · CA · contact PI
Disruption of AKT Pathway for Cancer Intervention$321,765
R01 · FY2006 · CA · contact PI
AKT2 Oncogene and Human Oncogenesis$235,398
R01 · FY2006 · CA · contact PI
Disruption of AKT Pathway for Cancer Intervention$322,111
R01 · FY2005 · CA
AKT2 Oncogene and Human Oncogenesis$241,063
R01 · FY2005 · CA
AKT1 Oncogene in Carcinogenesis$216,225
R01 · FY2005 · CA
Disruption of AKT Pathway for Cancer Intervention$319,642
R01 · FY2004 · CA
AKT2 Oncogene and Human Oncogenesis$241,063
R01 · FY2004 · CA
AKT1 Oncogene in Carcinogenesis$216,225
R01 · FY2004 · CA
AKT2 Oncogene and Human Oncogenesis$241,063
R01 · FY2003 · CA
AKT1 Oncogene in Carcinogenesis$216,225
R01 · FY2003 · CA
AKT1 Oncogene in Carcinogenesis$216,225
R01 · FY2002 · CA
AKT1 Oncogene in Carcinogenesis$216,225
R01 · FY2001 · CA
AKT2 ONCOGENE AND HUMAN ONCOGENESIS$107,833
R29 · FY2001 · CA
AKT2 ONCOGENE AND HUMAN ONCOGENESIS$104,574
R29 · FY2000 · CA